Triple Assay of Rectal Mucus in the Diagnosis of Colorectal Cancer
Trial statusRecruiting
Trial phaseNot listed
Trial typeObservational
Biological sexAll
Age18-99
SponsorOrigin Sciences
About this trial
Development of a multiomics assay for use on OriColTM sampled rectal mucus for detection of cancer and significant polyps in symptomatic patients on the Colorectal Urgent Suspected Cancer pathway.
Eligibility criteria
Qualifiers
Patients 18 years and over
Patients referred from primary care to the 'urgent suspected cancer' CRC pathway during the study period.
Patients who provide voluntary written informed consent to participate in the study.
Disqualifiers
Patients who are unable to undergo digital rectal examination (DRE).
Patients who have undergone radiotherapy.
An acute or chronic anal fissure
Perianal haematoma
Trial design
Treatments tested in this trial
- Oricol Test
Treatment groups
No treatment groups listed
Sponsors and collaborators
Origin Sciences
Lead sponsor
Shrewsbury and Telford Hospitals NHS Trust
Collaborator
Source ClinicalTrials.gov